Open Source Securities gives NuoCheng Jianhua a "Buy" rating: The company is expected to turn profitable by 2025, with accelerated global expansion of multiple products.

NightAirdropper · 2026-03-29T14:38:58+00:00

Open Source Securities gives NuCion Biotech a "Buy" rating, expecting that the increased sales of Obinutuzumab by 2025 will drive the company to turn profitable. The blood tumor and autoimmune markets will see key developments. Risks include pharmaceutical regulation, exchange rate fluctuations, and talent attrition.

NightAirdropper

2026-03-29 14:38:58

Abstract generation in progress

Everyday AI News reports that Open Source Securities published a research report on March 29, giving Nocera Biotechnology (688428.SH, latest price: 25.3 yuan) a “Buy” rating. The reasons for the rating primarily include: 1) Rapid volume growth of Obinutuzumab in 2025, with the company experiencing strong revenue growth and achieving profitability ahead of schedule; 2) The product matrix in the hematological oncology field becoming increasingly rich, with the first solid tumor product approved for market; 3) Deeply cultivating the self-immune blue ocean market, with multiple pipelines reaching critical milestones in 2026. Risk warning: Changes in pharmaceutical regulatory policies, exchange rate fluctuations, loss of core company members, etc.

Everyday Headlines (nbdtoutiao) — US-Iran war, “the twilight of the petrodollar”! The U.S. is unable to protect Gulf countries, oil trade is accelerating the move away from the dollar, former UK Chancellor: relying on the U.S. can no longer guarantee security!

(Reporter Zhang Xiwei)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Risks are borne by the operator.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.